Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Impact of Humidification on Sleep Quality During Home Non Invasive Ventilation (IMHUNIV)

14. mars 2019 oppdatert av: ADIR Association

Protocol Summary:

  1. Question Does the adjunction of a humidification system to non-invasive ventilation circuit improve sleep quality and comfort of chronic ventilated respiratory insufficient patients? Does it change the efficacy of long-term non invasive ventilation therapy and patient-ventilator interactions?
  2. Aims

Main aim:

The primary endpoint of this study is to objectively evaluate the consequences of a humidification system's adjunction on quality of sleep, 2 months after treatment's beginning.

Second aims:

The secondary endpoints are to evaluate the consequences of a humidification system's adjunction on non invasive ventilation's efficacy / patient-ventilator asynchronies / patients' comfort / treatment adherence.

Before the clinical trial, the investigators conducted a bench study using a mechanical lung in order to evaluate the ventilator's behavior with and without a humidification system.

The clinical trial will include patients with chronic respiratory failure with an indication of long-term non invasive ventilation therapy. Patients will be included in the Pulmonology, Thoracic Oncology and Respiratory intensive care unit of Rouen University Hospital.

It will be a prospective monocentric study, including consecutively all eligible patients. Informed consent will be obtained from all of them.

At baseline, patients will be hospitalized for two consecutive nights for non invasive ventilation's set up. During the first night, a polysomnography will be performed without non invasive ventilation. Then, patients will be treated by non invasive ventilation with a bi-level self-regulated pressure mode and an open circuit.

Patients will be randomized in two groups: without a humidification system and with a humidification system. Partitioning by the physiopathological pattern (obstructive versus obesity hypoventilation syndrome vs. neuromuscular disease) will be done.

During each night, arterial blood gases will be measured at bedtime and awakening. Patients will be monitored by:

  • polysomnography (only during the first night)
  • transcutaneous capnography
  • accessory inspiratory muscles surface electromyography
  • pneumotachograph on non invasive ventilation's circuit
  • pressions measured at the mask.

Follow-up will take place at two months after non invasive ventilation's beginning with or without humidification. Patients will be hospitalized for one night only. Blood gases at bedtime and at awakening will be measured. A polysomnography with non invasive ventilation will be performed. Observance will be evaluated.

Studieoversikt

Status

Fullført

Intervensjon / Behandling

Studietype

Intervensjonell

Registrering (Faktiske)

30

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

      • Bois-Guillaume, Frankrike, 76230
        • ADIR Association

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Type 2 chronic respiratory failure (PaCO2 > 6,5 at the time of the diagnosis)
  • Indication of a long term non invasive ventilation at home because of an obstructive respiratory disease, a obesity hypoventilation syndrome or a neuromuscular disease.
  • Over eighteen years old
  • Planned hospitalisation to introduce non invasive ventilation.

Exclusion Criteria:

  • Less than eighteen years old
  • Pregnancy
  • Psychiatric or cognitive disorders in wich consent is not possible
  • Acute respiratory failure within 2 weeks before inclusion.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Fukting
Patients will benefit of humidification and warming of delivered gaz by non-invasive ventilation thanks humidification system.
Ingen inngripen: Control group without humidification

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change from baseline in sleep quality at two month
Tidsramme: Assessement will be performed at baseline and 2 month after initiation of non invasive ventilation with or without humidification.
Sleep quality will be assessed by polysomnography without non invasive ventilation at Baseline versus with non invasive ventilation at follow up with or without humification (after 2month)
Assessement will be performed at baseline and 2 month after initiation of non invasive ventilation with or without humidification.

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Subjective sleep quality
Tidsramme: Assessement will be performed at baseline and 2 month after initiation of non invasive ventilation with or without humidification.
Outcome will be assessed using the Pittsburgh sleep quality index. The Pittsburgh Sleep Quality Index (PSQI) is a self-report questionnaire that assesses sleep quality over a one-month time interval. The measure consists of nineteen individual items, creating seven components which are summed to produce a global score. Each component ranges from zero to three (zero: no difficulty at all ; three: great difficulties). Global score ranges from zero (no difficulty) to twenty-one points (great difficulties).
Assessement will be performed at baseline and 2 month after initiation of non invasive ventilation with or without humidification.
Nature of patient-ventilator asynchrony
Tidsramme: Assessement will be performed at baseline and 2 month after initiation of non invasive ventilation with or without humidification.
Outcome will be assessed by two independent investigators through raw data from the ventilator
Assessement will be performed at baseline and 2 month after initiation of non invasive ventilation with or without humidification.
Number of patient-ventilator asynchrony
Tidsramme: Assessement will be performed at baseline and 2 month after initiation of non invasive ventilation with or without humidification.
Outcome will be assessed by two independent investigators through raw data from the ventilator
Assessement will be performed at baseline and 2 month after initiation of non invasive ventilation with or without humidification.
Comfort with non invasive ventilation
Tidsramme: Assessement will be performed at baseline and 2 month after initiation of non invasive ventilation with or without humidification.
Outcome will be assessed using a visual analogic scale ranging from zero to ten (zero: very uncomfortable ; ten: greater comfort).
Assessement will be performed at baseline and 2 month after initiation of non invasive ventilation with or without humidification.
Nasal obstruction
Tidsramme: Assessement will be performed at baseline and 2 month after initiation of non invasive ventilation with or without humidification.
Outcome will be assessed using the Nasal Obstruction Symptom Evaluation questionary (NOSE) which is an instrument allowing clinicians to better understand impact of nasal obstruction on patients' quality of life. The measure consists of five individual items evaluated on a one-month past interval. Each item ranges from zero (not a problem) to four (severe problem). Then, scores are summed to create a global score ranging from zero (not a problem) to twenty (severe problem).
Assessement will be performed at baseline and 2 month after initiation of non invasive ventilation with or without humidification.
Rhinorrhea and xerostomia
Tidsramme: Assessement will be performed at baseline and 2 month after initiation of non invasive ventilation with or without humidification.
Outcomes will be assessed using visual analogic scale ranging from zero to ten (zero: no rhinorrhea or xerostomia at all ; ten: worse rhinorrhea or xerostomia).
Assessement will be performed at baseline and 2 month after initiation of non invasive ventilation with or without humidification.
Quality of life: Severe Inspirator Insufficiency questionary
Tidsramme: Assessement will be performed at baseline and 2 month after initiation of non invasive ventilation with or without humidification.
Outcome will be assessed using the Severe Inspirator Insufficiency questionary. It's a specific instrument for measuring health-related quality of life in patients receiving home mechanical ventilation. The measure consists of forty-nine individual items, creating seven components which are summed to produce a global score. Each item ranges from one to five (one: not true ; five: very true). Each component ranges from zero to one hundred. Global score is the seven components' mean. It ranges from zero (bad quality of life) to one hundred percent (best quality of life).
Assessement will be performed at baseline and 2 month after initiation of non invasive ventilation with or without humidification.
Number of nightime disruption of non invasive ventilation
Tidsramme: Assessement will be performed at baseline and 2 month after initiation of non invasive ventilation with or without humidification.
Outcome will be assessed using raw data from the ventilator.
Assessement will be performed at baseline and 2 month after initiation of non invasive ventilation with or without humidification.
Adherence
Tidsramme: Outcome will be assessed at study completion (two months follow-up).
Number of hours of treatment by night
Outcome will be assessed at study completion (two months follow-up).

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Antoine Cuvelier, Prof, PhD, CHU-Hôpitaux de Rouen - Service de pneumologie, Hôpital de Bois-Guillaume, Rouen, France ; UPRES EA 3830, Institut de Recherche et d'Innovation Biomédicale de Haute-Normandie, Université de Rouen, Rouen, France
  • Hovedetterforsker: Maxime Patout, MD, MsC, CHU-Hôpitaux de Rouen - Service de pneumologie, Hôpital de Bois-Guillaume, Rouen, France ; UPRES EA 3830, Institut de Recherche et d'Innovation Biomédicale de Haute-Normandie, Université de Rouen, Rouen, France
  • Hovedetterforsker: Astrid Bertier, MD, CHU-Hôpitaux de Rouen - Service de pneumologie, Hôpital de Bois-Guillaume, Rouen, France ; UPRES EA 3830, Institut de Recherche et d'Innovation Biomédicale de Haute-Normandie, Université de Rouen, Rouen, France

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

21. mai 2018

Primær fullføring (Faktiske)

14. mars 2019

Studiet fullført (Faktiske)

14. mars 2019

Datoer for studieregistrering

Først innsendt

18. mai 2018

Først innsendt som oppfylte QC-kriteriene

18. juni 2018

Først lagt ut (Faktiske)

19. juni 2018

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

15. mars 2019

Siste oppdatering sendt inn som oppfylte QC-kriteriene

14. mars 2019

Sist bekreftet

1. mars 2019

Mer informasjon

Begreper knyttet til denne studien

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Kliniske studier på Humidification

3
Abonnere